Q1 2018 Investor Conference Call

Thursday, May 3, 2018
Start at approx. 2:00 p.m. CEST (12:00 noon UTC)

Investor News May 03, 2018

First quarter of 2018:

Bayer: Operational business held back by currency effects - Major progress with Monsanto acquisition

Group sales increase by 2.0 percent (Fx & portfolio adj.) to 9.138 billion euros / EBITDA before special items down year on year at 2.896 billion euros due to currency effects - level with prior-year quarter on a currency-adjusted basis / Sales increase at Pharmaceuticals (Fx & portfolio adj.) / Consumer Health down year on year, as expected / Sales of Crop Science match strong prior-year quarter (Fx & portfolio adj.) / Animal Health raises sales (Fx & portfolio adj.) and earnings / Net income declines by 6.2 percent to 1.954 billion euros / Core earnings per share down 1.3 percent at 2.28 euros / European Commission and additional regulators conditionally approve Monsanto acquisition / Currency adjusted Group outlook for 2018 confirmed


Werner Baumann
CEO of Bayer AG

Audio recording of the presentations and discussion


Audio file

You can also play the audio recording on your mobile device.


Presentation charts


Johannes Dietsch
CFO of Bayer AG

Interim Report First Quarter 2018

Q1 2018 Analyst and Investor Briefing


Q1 2018 All in One Package for Investors and Analysts